Abstract
Head and neck squamous cell carcinoma (HNSCC) accounts for nearly 5% of global cancer deaths per year, with epidemiological studies suggesting an expected 30% increase in cases by 2030 due to rising incidence of viral infection (i.e. huma papilloma virus [HPV]). Treatment consists primarily of surgical tumor removal accompanied by post-operative chemoradiation therapy; however, disease recurrence is still an issue amongst 10–26% of patients. Doublecortin-like kinase 1 (DCLK1) is a microtubule-associated protein with dual kinase activity, and upregulation has been associated with poor prognosis in multiple solid tumors. Recent studies by Arnold et al. highlighted a definitive role of DCLK1 in HNSCC invadopodium formation and function, and has elucidated its potential for small molecule targeting. This commentary summarizes the molecular findings by Arnold et al. and evaluates them in regard to the current standings of DCLK1 targeting, emphasizing why inhibiting this molecule could be of clinical significance.
Keywords
Head and neck squamous cell carcinoma, Squamous cell carcinomas, Tumors